HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Compston, J. Search for Related Content PubMed Articles by Compston, J.

Management of Glucocorticoid-Induced Osteoporosis – for Neurologists

Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge UK; Email: jec1001{at}cam.ac.uk

EXTRACT

INTRODUCTION

Glucocorticoids are widely used by a number of medical specialists, including neurologists. A recent study using the UK General Practice Research Database identified 1.6 million oral glucocorticoid prescriptions over a 10-year period in 683 practices from different geographic areas of the UK (van Staa et al. 2000). At any one time, the prevalence of oral glucocorticoid use was 0.9% of the total adult population, rising to 2.5% of those aged 70–79 years. However, the use of bone active medication in this population was extremely low (5% used hormone replacement therapy and only 1.8% used bisphosphonates). And yet, osteoporosis is a common and serious complication of treatment with glucocorticoids, being associated with an increased risk of vertebral and hip fractures.

Some important characteristics of glucocorticoid-induced bone loss have recently been identified:

• Even during the first few months of therapy the onset of bone loss is rapid and the
  

[PDF of this article]